Abstract
Discover how HepatoXcell™ hepatocytes deliver sustained metabolic activity in advanced liver-chip platforms that replicate the dynamic microenvironment of the human liver. By integrating HepatoXcell™ into two distinct microfluidic designs—a flat-bed and a 3D meshed-bed—we demonstrate prolonged hepatocyte functionality and viability. These platforms simulate physiological conditions such as fluid flow and cell-cell interactions, enabling more predictive models for drug metabolism, toxicity testing, and disease research.
Download the presentation to see how HepatoXcell™ delivers sustained metabolic activity in advanced liver-chip platforms
DownloadPresenter
Carolina Lucchesi, PhD
Principal Scientist, BioNexus, ATCC
Carolina Lucchesi is BioNexus Foundation Principal Scientist leading the Microphysiological Systems program at ATCC. Dr. Lucchesi received her PhD in Cellular and Molecular Biology from the University of Campinas in Brazil and has over 20 years of experience in Tissue Engineering and Organ-on-Chip technology. In her current role, Dr. Lucchesi leads the MPS program bringing new capabilities in the use of advanced 3D models and developing existing and new content to be applied in state-of-art technologies.
Primary human hepatocytes are considered the gold standard for in vitro liver models due to their high predictive value in drug metabolism and toxicity studies. They can provide early insights into how a drug will behave in the human body, potentially reducing the risk of adverse effects in clinical trials. ATCC hepatocytes are meticulously isolated and characterized to ensure the highest quality and performance for your drug development and toxicity testing needs. Try our HepatoXcell™ primary human hepatocytes and media today!
Learn more
